We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-14.72%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$9.59M
AUM Growth
-$434M
Cap. Flow
-$279M
Cap. Flow %
-2,907.54%
Top 10 Hldgs %
47.01%
Holding
85
New
15
Increased
1
Reduced
62
Closed
7

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$2.17M
2
REGN icon
Regeneron Pharmaceuticals
REGN
+$1.24M
3
BNTX icon
BioNTech
BNTX
+$588K
4
LKFT
Lakefront Biotherapeutics American Depositary Shares
LKFT
+$408K
5
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$180K

Top Sells

Rank Stock Value
1
INCY icon
Incyte
INCY
+$16.7M
2
NBIX icon
Neurocrine Biosciences
NBIX
+$16.6M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$15.2M
4
PTCT icon
PTC Therapeutics
PTCT
+$14.4M
5
AMGN icon
Amgen
AMGN
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.54%
2 Miscellaneous 0.46%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CNCE
1
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
$620K 6.47%
+2,610
New +$10.3K
AUPH icon
2
Aurinia Pharmaceuticals
AUPH
$2.2B
$574K 5.98%
5,758
-429,242
-99% -$4.8M
DYN icon
3
Dyne Therapeutics
DYN
$4.87B
$563K 5.87%
3,865
-472,135
-99% -$3.25M
NBP
4
NovaBridge Biosciences American Depositary Shares
NBP
$221M
$553K 5.77%
6,232
-11,768
-65% -$141K
QURE icon
5
uniQure
QURE
$3.47B
$447K 4.66%
8,318
-147,182
-95% -$2.34M
KALV
6
DELISTED
KalVista Pharmaceuticals
KALV
$383K 4%
3,760
-379,473
-99% -$4.19M
TVTX icon
7
Travere Therapeutics
TVTX
$6.31B
$380K 3.96%
9,215
-370,785
-98% -$9.32M
EXEL icon
8
Exelixis
EXEL
$13.7B
$350K 3.65%
+7,290
New +$150K
KDNY
9
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$340K 3.55%
5,947
-334,442
-98% -$5.25M
SUPN icon
10
Supernus Pharmaceuticals
SUPN
$2.57B
$298K 3.1%
8,604
-288,896
-97% -$8.27M
HZNP
11
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$287K 2.99%
22,915
-160,558
-88% -$15.2M
VERA icon
12
Vera Therapeutics
VERA
$2.48B
$281K 2.93%
3,825
-186,924
-98% -$3.26M
IOVA icon
13
Iovance Biotherapeutics
IOVA
$3.74B
$273K 2.85%
3,011
-54,989
-95% -$721K
CRBU icon
14
Caribou Biosciences
CRBU
$178M
$255K 2.66%
+1,378
New +$10.5K
INCY icon
15
Incyte
INCY
$25.9B
$238K 2.48%
18,081
-219,919
-92% -$16.7M
NBIX icon
16
Neurocrine Biosciences
NBIX
$15.8B
$236K 2.46%
23,008
-179,992
-89% -$16.6M
HRMY icon
17
Harmony Biosciences
HRMY
$2.31B
$222K 2.31%
10,794
-194,680
-95% -$8.76M
FULC icon
18
Fulcrum Therapeutics
FULC
$293M
$194K 2.02%
949
-81,792
-99% -$799K
RARE icon
19
Ultragenyx Pharmaceutical
RARE
$2.58B
$161K 1.68%
9,610
-223,490
-96% -$13.8M
FATE icon
20
Fate Therapeutics
FATE
$304M
$158K 1.65%
3,917
-24,083
-86% -$664K
GILD icon
21
Gilead Sciences
GILD
$184B
$146K 1.52%
9,012
-79,772
-90% -$4.94M
MRTX
22
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$136K 1.42%
9,131
-179,369
-95% -$11.4M
NVAX icon
23
Novavax
NVAX
$1.5B
$133K 1.38%
6,814
-125,686
-95% -$6.51M
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.92B
$123K 1.29%
+6,876
New +$408K
CCXI
25
DELISTED
ChemoCentryx, Inc.
CCXI
$121K 1.26%
3,000
-33,100
-92% -$730K
1
2 3 4

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q2 2022 Portfolio in Review

As of Q2 2022, International Biotechnology Trust held 85 positions worth $9.59M, down 98% from $443M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

International Biotechnology Trust withdrew a net $279M in Q2 2022, closing 7 positions and reducing 62 holdings. Its most notable exit was Biohaven Pharmaceutical Holding Company Ltd., an estimated $9.29M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier, followed by Miscellaneous.

Against the trend, International Biotechnology Trust opened a new position in Biogen worth $52K.

  • International Biotechnology Trust's largest Q2 2022 buy was Biogen: 10,606 shares worth $52K.
  • International Biotechnology Trust added most to Regeneron Pharmaceuticals in Q2 2022, an estimated $1.24M increase.
  • International Biotechnology Trust's biggest Q2 2022 reduction was Incyte, cutting an estimated $16.7M.
  • International Biotechnology Trust fully exited Biohaven Pharmaceutical Holding Company Ltd. in Q2 2022, selling an estimated $9.29M.
  • International Biotechnology Trust's ten largest holdings make up 47% of its $9.59M portfolio in Q2 2022.
  • International Biotechnology Trust opened 15 new positions and closed 7 in Q2 2022.
  • International Biotechnology Trust's portfolio value fell 98% quarter-over-quarter to $9.59M.

Based on International Biotechnology Trust's 13F filing for Q2 2022, filed 16 Aug 2022.